Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has approved Novocure Ltd's (NASDAQ: NVCR) Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR Phase 3 trial to 276 patients with 12 months follow-up.
- The trial is testing the effectiveness of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel for patients with stage 4 non-small cell lung cancer (NSCLC) who progressed during or after platinum-based therapy.
- The independent data monitoring committee (DMC) recommended reducing the sample size, which it believes will provide sufficient overall power for both primary and secondary endpoints.
- Novocure remains blinded to all data.
- Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing cancer cells to die.
- Price Action: NVCR shares closed at $175 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!